Tenaya Therapeutics (TNYA)
(Delayed Data from NSDQ)
$1.99 USD
-0.01 (-0.50%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $1.98 -0.01 (-0.50%) 4:46 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Tenaya Therapeutics, Inc. [TNYA]
Reports for Purchase
Showing records 1 - 14 ( 14 total )
Company: Tenaya Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; Cardiovascular Pipeline Keeps Beating Strong; MyPeak-1 Phase 1b Interim Data in 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tenaya Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; ASGCT ''23 Presentations Raise Profile of AAV Therapy in CV Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tenaya Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Cardiovascular Pipeline Continues Its Ascent; Initial MyPeak-1 Phase 1b Data Expected in 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tenaya Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Heartfelt Progress Continues With Cardiovascular Therapies; Initial MyPeak-1 Phase 1b Data in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tenaya Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TN-401 Receives Green Light From FDA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tenaya Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Important Profile Building Data Points; Look for HFpEF Patients Targeted Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tenaya Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TN-201 Begins Its Climb to the Summit; First Patient Dosed in MyPeak-1 Phase 1b Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tenaya Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; All Eyes on TN-201 as Phase 1b Trial Start Approaches; TN-301 Data in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tenaya Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; TN-301 Phase 1 Data in 2H23; Series of Presos Supporting RD Capabilities at ASGCT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tenaya Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; Trio of Cardiovascular Therapies With Milestones in 2H23; Target Adjusted to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tenaya Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Pipeline Growing With TN-201 Trial Initiation, TN-401 IND Submission, and TN-301 Phase 1 Data in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tenaya Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Journey Sets Off With Phase 1 Trial of TN-301 For Heart Failure in Healthy Volunteers
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tenaya Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Getting Closer to Clinical Stage With Multiple IND Submissions Planned for the Year Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Tenaya Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Multi-Modal Platform to Target CV Diseases; Initiating With Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BRANCHETTI E
|